NEW YORK, May 14, 2019 /PRNewswire/ -- Hoth Therapeutics,
Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique
targeted therapeutics for patients suffering from indications such
as atopic dermatitis–also known as eczema–as well
as dermatological and chronic wound disorders, today announced
that the company has signed a term sheet with Zylö Therapeutics Inc
(Zylö) to co-develop a new treatment for patients suffering from
Cutaneous Lupus Erythematosus (CLE). CLE is a
chronic autoimmune disease that affects the skin.
Zylö, dedicated to bringing innovative technologies to multiple
facets of medicine, has an innovative sustained-release
drug-delivery system that was developed by Joel Friedman MD PhD, Adam Friedman MD FAAD, and Andrew Draganski PhD.
The delivery system uses patented xerogel-derived nanoparticles,
called Z-pods™, to deliver—in a sustained and controlled
manner—notoriously hard-to-deliver therapeutic agents through
topical administration. For more information, please visit;
http://www.zylotherapeutics.com/
Scientists at Einstein College of Medicine recently demonstrated
that topical administration with AEA-loaded nanoparticles
significantly prevents the development of CLE in an established
animal model of lupus. This work reinforces and highlights the
utility of targeting the endocannabinoid system for autoimmune
rheumatic diseases.
The work at Einstein supports the thesis that AEA loaded into
Z-pods™ improves drug skin penetration, reduces the expected
inflammatory cytokine secretion by keratinocytes when exposed to
ultraviolet radiation, prevents the development of CLE skin
lesions, improves skin histopathology, prevents inflammation and
structural damage on histology and reduces macrophages and C3
accumulation.
According to estimates by the Lupus Foundation of America
(LFA), 1.5 Million Americans currently suffer from lupus,
with 16,000 new cases reported annually. Tragically, lupus
strikes mostly women of child-bearing age. Worldwide, the
LFA estimates that at least five million people may have some
form of the disease. Of the people diagnosed, approximately
two-thirds will develop CLE. The annual average cost to provide
medical treatment for a person with lupus: $6,000 to $10,000,
with some treatment costing several thousand dollars a month.
"Management is extremely pleased to partner with Zylö
Therapeutics, enhancing our portfolio of unique treatments for
patients suffering from various dermatological related ailments,"
stated, Mr. Robb Knie, CEO of Hoth
Therapeutics. "Zylö's initial work shows significant promise
in combating Cutaneous Lupus Erythematosus, and we look forward to
working with them in order to bring this treatment to market."
"We are thrilled to partner with Hoth, a company that is
committed to innovative solutions and partnerships to develop
treatments for diseases with a high unmet clinical need, such as
lupus," said Scott Pancoast, CEO of
Zylö. "As we work with the Hoth team to advance AEA-loaded Z-pods
through the next stages of development, we expect to further
demonstrate the important role that our patented Z-pod delivery
system plays in improving treatment outcomes."
The term sheet is non-binding and neither party thereto shall
have any obligation to consummate a transaction of any kind until
such time as the parties have entered into a mutually agreeable
definitive agreement. There can be no assurance that any such
definitive agreement will be entered into or that the transaction
will be completed on the terms set forth in the term sheet, or at
all.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc., a Nevada corporation, is a
biopharmaceutical company focused on unique targeted therapeutics
for patients suffering from indications such as atopic dermatitis,
also known as eczema. Hoth has exclusive worldwide rights to the
BioLexa Platform.
Forward Looking Statements
This press release includes "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements in this press release include, but
are not limited to, statements that relate to the advancement and
development of the BioLexa Platform, the commencement of clinical
trials, the availability of data from clinical trials and other
information that is not historical information. When used herein,
words such as "anticipate", "being", "will", "plan", "may",
"continue", and similar expressions are intended to identify
forward-looking statements. In addition, any statements or
information that refer to expectations, beliefs, plans,
projections, objectives, performance or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking. All forward-looking statements
are based upon Hoth's current expectations and various assumptions.
Hoth believes there is a reasonable basis for its expectations and
beliefs, but they are inherently uncertain. Hoth may not realize
its expectations, and its beliefs may not prove correct. Actual
results could differ materially from those described or implied by
such forward-looking statements as a result of various important
factors, including, without limitation, market conditions and the
factors described under the caption "Risk Factors" in Hoth's Form
10K for the period ending December 31, 2018, and Hoth's other
filings made with the Securities and Exchange Commission.
Consequently, forward-looking statements should be regarded solely
as Hoth's current plans, estimates and beliefs. Investors should
not place undue reliance on forward-looking statements. Hoth cannot
guarantee future results, events, levels of activity, performance
or achievements. Hoth does not undertake and specifically declines
any obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by law.
Contact
Investor Relations Contact:
Phone: (646) 756-2997
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-signs-term-sheet-with-zylo-therapeutics-to-acquire-a-license-and-jointly-develop-a-product-to-treat-lupus-300849348.html
SOURCE Hoth Therapeutics, Inc.